Taeyoung to Sack Executives, Cut Employees' Salaries to Save Company 
5 Reasons Businesses Can’t Afford Not to Get Fleet Maintenance Software 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
Hyundai Halts Advertising on X Amid Antisemitism Row 
Adidas Unveils Innovative Team Kits for Paris 2024 Olympics and Paralympics 
Polestar to Launch Polestar 4 Pure EV in South Korea 
Mister Donut and Gion Tsujiri Unite Once More for Kyoto-Inspired Donut Delights 
Tesla Cybertruck Recall: NHTSA Flags 3,878 Units for Pedal Issue 
TSMC to Hike Prices for Chips Made Outside Taiwan, Impacting Global Device Costs 
Low pay and few contracts make freelance journalism a bleak prospect in 2024 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Meta AI to Supercharge WhatsApp, Facebook, Instagram via Powerful Integration 
SPC Group’s Paris Baguette Inaugurates First Bakery Shop in the Philippines 
Kawhi Leonard and New Balance Launch the Highly Anticipated KAWHI IV Sneaker 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
Tesla Dismisses 285 Buffalo, New York Workers in Restructuring Efforts 
Sony Pictures, Apollo Global Reportedly In Talks to Jointly Bid for Paramount 
STAMFORD, Conn., Sept. 02, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 10:30 a.m. ET in New York.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
